Statement of Changes in Beneficial Ownership (4)
November 18 2020 - 4:16PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Dillione Janet |
2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc.
[
CRMD
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O CORMEDIX INC., 300 CONNELL DRIVE, SUITE 4200 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/16/2020 |
(Street)
BERKELEY HEIGHTS, NJ 07922
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | | | | | | | | 53473.0000 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Phantom Stock | $0.0000 | 11/16/2020 | | A | | 3583.0000 | | (1) | (1) | Common Stock | 3583.0000 | $0.0000 | 3583.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 4770.0000 | | 4770.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 5253.0000 | | 5253.0000 | D | |
Stock Option (Right to Buy Common Stock) | $5.6300 | | | | | | | (2) | 2/25/2030 | Common Stock | 15000.0000 | | 15000.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 1706.0000 | | 1706.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 2099.0000 | | 2099.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 945.0000 | | 945.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 1126.0000 | | 1126.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 843.0000 | | 843.0000 | D | |
Stock Option (Right to Buy Common Stock) | $8.3000 | | | | | | | (3) | 1/10/2029 | Common Stock | 15000.0000 | | 15000.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 1328.0000 | | 1328.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 2728.0000 | | 2728.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 7500.0000 | | 7500.0000 | D | |
Stock Option (Right to Buy Common Stock) | $2.8500 | | | | | | | (4) | 2/16/2028 | Common Stock | 8000.0000 | | 8000.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 2679.0000 | | 2679.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 3125.0000 | | 3125.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 4167.0000 | | 4167.0000 | D | |
Stock Option (Right to Buy Common Stock) | $11.2000 | | | | | | | (5) | 2/21/2027 | Common Stock | 8000.0000 | | 8000.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 695.0000 | | 695.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 829.0000 | | 829.0000 | D | |
Stock Option (Right to Buy Common Stock) | $15.1500 | | | | | | | (6) | 8/11/2025 | Common Stock | 10000.0000 | | 10000.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 283.0000 | | 283.0000 | D | |
Stock Option (Right to Buy Common Stock) | $9.5500 | | | | | | | (7) | 2/21/2026 | Common Stock | 19000.0000 | | 19000.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 767.0000 | | 767.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 554.0000 | | 554.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 867.0000 | | 867.0000 | D | |
Phantom Stock | $0.0000 | | | | | | | (1) | (1) | Common Stock | 3062.0000 | | 3062.0000 | D | |
Explanation of Responses: |
(1) | Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director. |
(2) | These options were granted on 02/25/2020. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. |
(3) | These options were granted on 01/10/2019. These options are fully vested. |
(4) | These options were granted on 02/16/2018. These options are fully vested. |
(5) | These options were granted on 02/21/2017. These options are fully vested. |
(6) | These options were granted on 08/12/2015. These options are fully vested. |
(7) | These options were granted on 02/21/2016. These options are fully vested. |
Remarks: The Issuer effected a 1-for-5 reverse stock split of its common stock on March 26, 2019. All share and per share exercise price amounts shown in this Form 4 have been adjusted to reflect the reverse stock split. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Dillione Janet C/O CORMEDIX INC. 300 CONNELL DRIVE, SUITE 4200 BERKELEY HEIGHTS, NJ 07922 | X |
|
|
|
Signatures
|
/s/ Janet Dillione | | 11/18/2020 |
**Signature of Reporting Person | Date |
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Sep 2023 to Sep 2024